BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

As President Donald Trump lands in Beijing, one major industry is missing from his business delegation—pharma. | As President ...

With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...

Haleon has completed a hat-trick of recent soccer initiatives, inking a pain management partnership with the organization ...

Pfizer and Arvinas have landed a buyer for the newly approved breast cancer med Veppanu, selling an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and potentially hundreds ...

Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate Lumryz met all primary and key secondary ...

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin Pharmaceutical is ...

Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...

Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the ...

Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules ...